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Adjuvant chemotherapy in the patients with rectal cancer after 
neoadjuvant chemoradiotherapy and radical resection — YES
Rafał Stec
At the moment there are some scientific data supporting the use of adjuvant chemotherapy in patients with rectal 
cancer after neoadjuvant chemoradiotherapy and surgical treatment. The paper below presents some arguments for 
the use of adjuvant chemotherapy in the above clinical situation. The majority of deaths in patients with rectal cancer 
are caused by the presence of distant metastases, therefore there are significant grounds for the use of adjuvant che-
motherapy in this group of patients. Summarising, there is no clear or scientific evidence against the use of adjuvant 
chemotherapy in patients with rectal cancer after preoperative chemoradiotherapy. In order to make a conclusive 
statement about the lack of any benefits from adjuvant therapy, it is necessary to carry out randomised studies on a 
homogeneous and standardised group of patients. Therefore, it seems appropriate to apply this therapy especially 
for patients with the N (+) features (with a tumour location between 10 cm and 15 cm), similar to colon cancer cases.
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Currently there is some scientific evidence supporting 
the use of adjuvant chemotherapy in patients with rectal 
cancer after neoadjuvant chemoradiotherapy and surgical 
treatment. The arguments for the usage of adjuvant therapy 
in such clinical conditions are presented below.
The majority of deaths in patients with rectal cancer are 
caused by the presence of distant metastases [1], therefore 
there are some essential grounds for the use of adjuvant 
chemotherapy in this group of patients. The task of adjuvant 
chemotherapy is to destroy micro-metastatic lesions, which 
remain invisible in imaging diagnostics.
Both surgical treatment and radiotherapy are solely 
the methods of local treatment, so their purpose is not the 
“liquidation” of the distant metastases. Fluoropyrimidines, in 
combination with radiotherapy, in neoadjuvant treatment 
are not used in doses which are systematically active (two 
courses are administered in the first and the fifth week of 
radiotherapy or three courses according to the de Gramont 
regimen as a consolidation therapy after a “short” radio-
therapy) [1], that is why adjuvant chemotherapy should be 
used especially in patients with cancer dissemination risk 
factors, such as the presence of “positive” lymph nodes (N+ 
stage) or T4 stage.
A significant improvement in the efficiency of adjuvant 
chemotherapy in the third stage of colon cancer was ob-
tained by adding oxaliplatin to the 2-drug regimen (5-flu-
orouracil and folinic acid). In the “MOSAIC” trial (André et 
al. 2015) the 10-year OS (overall survival) was 67.1% for the 
patient group treated with the chemotherapy with oxalipla-
tin regimen (FOLFOX 4) compared to 59.0% for the group 
of patients treated solely with 5-fluorouracil and folinic ac 
id) (HR = 0.80; p = 0.016) [2]. We have to remember that 
this was a colon cancer whose treatment method differs 
significantly from that applied for rectal cancer, yet with 
the proper patient selection (the third disease stage) and 
with the use of the more effective chemotherapy regimen 
(based on oxaliplatin), a significant and desired objective 
can be achieved, i.e. the improvement of survival factors.
In the EORTC 22921 randomised trial (Bosset et al. 2014), 
1011 patients with rectal cancer were randomly distributed 
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into 4 groups: the first two were treated with preoperative 
radiotherapy or radio-chemotherapy, whilst the next two 
groups received adjuvant chemotherapy, after neoadju-
vant therapy and after surgical intervention. No statistically 
significant improvement was obtained with regards to DFS 
(disease-free survival), or to OS; the 10-year DFS was 47.0% 
in the patient group treated with adjuvant chemotherapy 
as compared with 43.7% in the group of patients under-
going observation alone (HR = 0.91; 95% CI 0.77–1.08; p = 
0.29), whilst the 10-year OS was 51.8% as compared with 
48.4% respectively (HR = 0.91; 95% CI 0.77–1.09, p = 0.32). 
It must be stressed that the evaluation of the efficiency of 
the applied adjuvant chemotherapy in patients with rectal 
cancer undergoing previously neoadjuvant radiotherapy 
or chemoradiotherapy, did not comprise the analysis of the 
subjects with N (+) stage (statistical analysis of the patients 
was based solely on the T stage), whereas this is precisely 
the group which might benefit most from the adjuvant 
treatment, like in the case of colon cancer patients; also here 
a suboptimal chemotherapy was used (without oxaliplatin), 
which is normally used in the adjuvant treatment of the 
colon cancer patients [2, 3]. The lack of efficiency of the 
adjuvant chemotherapy applied after preoperative chemo-
radiotherapy and after surgical intervention was presented 
in another third phase randomised clinical trial (Aldo et al. 
2014). The patients (655 patients) were randomly distributed 
to the two study arms: arm A comprised patients treated 
preoperatively with chemoradiotherapy and then under ob-
servation alone, whilst arm B were patients who additionally 
received 6 courses of adjuvant chemotherapy according to 
the regimen: 5-fluorouracil with folinic acid. No significant 
differences between A and B groups were achieved with 
regards to the 5-year DFS and 5-year OS: 62.8% vs 65.3% 
(p = 08.82) and 70% vs 69.1% (p = 0.772) respectively. In 
spite of the definite results of the study, a number of doubts 
linger: a significantly lower rate of patients in the N(+) stage 
were included in the study, but they are the most important 
target group for the use of adjuvant chemotherapy and, 
what is more these patients were included into the specific 
study arms in different manners: in arm A there were 24.5% 
patients, whereas in arm B 34.6% (29.7% of the total entire 
patient population). Some other doubts concern the lack 
of important clinical and pathomorphological data — in 
13.2% patients, the N stage was marked as Nx. This would 
mean that in spite of a poorer prognosis in arm B (a higher 
rate of patients in the N+ stage) similar results in survival 
were obtained. The lack of significant improvement in both 
DFS and OS could also be the outcome of the application 
of a suboptimal chemotherapy regimen: 5-fluorouracil with 
folinic acid (without oxaliplatin) [4].
Another third-phase randomised clinical trial, prepared 
by the Dutch group, “PROCTOR-SCRIPT” (Breugom et al. 
2015), in which 437 patients were included (221 subjects 
in the observation group and 216 patients treated with ad-
juvant chemotherapy), also failed to confirm the efficiency 
of adjuvant chemotherapy. The 5-year OS for the group 
undergoing observation alone was 79.2% vs 80.4% in the 
group treated with adjuvant chemotherapy (HR = 0.93; 95% 
CI 0.62–1.39; p = 0.73; HR for DFS was 0.80; 95% CI 0.60–1.07; 
p = 0,13), whilst the 5-year cumulative frequency of loco-
-regional relapse was 7.8% for both groups and the 5-year 
cumulative frequency of distant metastases was 38.5% vs 
34.7% respectively (p = 0.39). Nevertheless, in the analysis of 
the patient characteristics, it must be emphasised that the 
rate of patients who received neoadjuvant chemotherapy 
before the adjuvant chemotherapy was only 14.0% for both 
groups (12.7% in the group with observation alone and 
15.3% in the group treated with adjuvant chemotherapy), 
which makes it impossible to draw reliable conclusions in 
this group of patients. Moreover, chemotherapy was based 
on 5-fluorouracil or capecitabin, without oxaliplatin [5].
The benefit in the use of adjuvant chemotherapy (Hong 
et al. 2014) was obtained in the second-phase clinical trial, 
“ADORE” (“ADjuvant Oxaliplatin in REctal cancer”). The study 
comprised 321 rectal cancer patients in the second and third 
stage (ypT3–4N0 or any ypT, N1–2 in screening) after neo-
adjuvant chemotherapy. Adjuvant chemotherapy consisted 
of a 2-drug regimen: 5-fluorouracil with folinic acid or the 
FOLFOX regimen in the second group. Some improvement 
with regards to the 3-year DFS was obtained for the patient 
group receiving chemotherapy based on the FOLFOX re-
gimen in comparison with the patient group treated with 
5-fluorouracil with folinic acid (71.6% vs 62.9%; HR = 0.657; 
95% CI 0.434–0.994; p = 0.047). Some particular benefit 
with regards to the 3-year DFS was obtained in the group 
of patients with the third stage disease in comparison with 
patients with the second stage (66.6% vs 57.3%; HR = 0.602; 
95% CI 0.371–0.977; p = 0.040) and (81.6% vs 71.3%; HR = 
0,744, 95% CI 0,334–1,657; p = 0,47) respectively. The 3-year 
OS also turned out to be better in the group of patients 
receiving the chemotherapy regimen based on oxalipla-
tin in comparison with the group of patients treated with 
the 2-drug regimen (95.0% vs 85.7%; HR = 0.456, 95% CI 
0.215–0.970; p = 0.036). Summing up this study, it must be 
stressed that the largest benefit in adjuvant treatment was 
gained by the patients with the third stage disease, which 
correlates with the results of adjuvant treatment in colon 
cancer [6].
The metanalysis which shows the lack of any benefit 
in such a course of treatment is that which is presented 
by Breugom et al. in 2015, which comprised 4 third-phase 
randomised clinical trials (1198 rectal cancer patient in total: 
“I-CNR-RT”, “PROCTOR-SCRIPT”, “EORTC 2292”, “CHRONICLE”), 
in which adjuvant treatment consisted in a chemotherapy 
regimen based on 5-fluorouracil (3 trials), capecitabine (1 
study) or XELOX regimen (1 study). No significant benefit was 
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shown in the entire patient population with regards to the 
OS with the use of adjuvant chemotherapy after a preope-
rative neoadjuvant chemoradiotherapy (HR = 0.97; 95% CI 
0.81–1.17; p = 0.775). However, in the subgroup analysis, a 
significant improvement in DFS and remote recurrence was 
obtained in patients with the location of the primary tumour 
between 10 cm and 15 cm from the edge of the anus (HR 
= 0.59; 95% CI 0.40–0.85; p = 0.005 and HR = 0.61, 95% CI 
0.40–0.94; p = 0.025 respectively). In the discussion of the 
metanalysis, the heterogenicity (the lack of homogeneity of 
the results) of the studies qualified for evaluation. In spite 
of the lack of proof with regards to significant differences 
to the heterogenicity of the qualified studies, some signi-
ficant incompliances concerned, among others, different 
chemotherapy regimens applied in the adjuvant treatment, 
various regimens of preoperative therapy, taking into con-
sideration the rate of the patients who were undergoing 
radiotherapy alone (2 studies), the diverse moment of the 
randomisation of the patients (randomisation before or 
after surgical treatment) or different standards of surgical 
intervention (total mesorectal excision and radical surgical 
intervention). Taking into consideration the doubts presen-
ted above, one cannot draw definite conclusions concerning 
the lack of efficiency of adjuvant chemotherapy in rectal 
cancer patients after preoperative treatment combined 
with chemoradiotherapy [7].
In another metanalysis (5 randomised clinical trials, 
2398 patients), there was no statistically significant benefit 
in the use of adjuvant chemotherapy in comparison with 
the group undergoing observation alone among the rectal 
cancer patients after preoperative radiotherapy or radio-
-chemotherapy (Bujko et al. 2015). The differences both in 
OS and DFS were not statistically significant between the 
group with chemotherapy and the group of patients without 
adjuvant treatment (HR = 0.95; 95% CI 0.82–1.10; p = 0.49 
and HR = 0.92; 95% CI 0.80–1.04; p = 0.19) respectively. 
Also no statistically significant difference was obtained with 
regards to DFS (4 randomised clinical trials, 2710 patients) 
between the group on chemotherapy based on oxaliplatin 
and the group of patients without oxaliplatin (HR = 0.84, 
95% CI 0.66–1.06; p = 0.15) in spite of the fact that in two 
of four analysed trials there was a statistically significant 
difference in DFS to the advantage of the patients treated 
in chemotherapy with oxaliplatin.
Similarly as in the case of other clinical trials or meta-
nalyses, a number of doubts arise, concerning the limited 
population of patients included into specific clinical trials, 
which makes it impossible to catch differences smaller than 
3–5% with respect to the 5-year OS (type II error), subopti-
mal methodology (e.g. randomisation before preoperative 
treatment which decreases the possibilities of observing 
the effect of post-operative chemotherapy), diverse patient 
groups included into the trials and metanalyses (e.g. pre-
operative radiotherapy, varied disease stages without N+ 
a stage or even ypT0N0 stage or the first stage of disease), 
and also the fact in 3 of 9 studies in the metanalysis, only 
abstracts were available (no reviews, which always present 
the discussion of the obtained results) [8].
In a systematic review and metanalysis (in total 4 rando-
mised clinical trials: “CAO/ARO/ AIO-04”, “PETACC-6”, “ADORE” 
and ”CHRONICLE”) published by Zhao L et al. (2016), the final 
analysis concerned 2793 rectal cancer patients in the second 
or third disease stage, who, after preliminary treatment with 
chemoradiotherapy followed by a surgical intervention, 
received adjuvant treatment consisting in chemotherapy 
regimens composed of capecitabine/5-fluorouracil/5-flu-
orouracil with folinic acid or underwent observation alone 
(one group) or chemotherapy regimens containing oxali-
platin in connection with 5-fluorouracil and folinic acid or 
capecitabine (the second group). In the group of patients 
treated according to chemotherapy regimens containing 
oxaliplatin, in comparison with the chemotherapy regimens 
without this drug, a statistically significant prolongation of 
DFS as the primary endpoint was obtained (HR = 0.85; 95% 
CI 0.73–0.98; p = 0.03), but no OS prolongation was obtained 
— and this was the secondary study endpoint (HR = 0.64; 
95% CI 0.35–1.17; p = 0.15). In the presented metanalysis, 
the qualified studies differed significantly from each other, 
among others by the chemotherapy regimens (oxaliplatin 
was used in preoperative treatment only in two studies) and 
the planned recruitment was not completed (“CHRONICLE” 
study). Moreover, in three trials, adjuvant chemotherapy 
comprised patients with complete pathological remission 
after the ypCR treatment (ypT0N0M0) or the first disease sta-
ge (the group of patients who do not benefit from adjuvant 
therapy). In three trials, the rate of patients who completed 
the planned treatment in total or who received the majority 
of the chemotherapy courses totalled 43% to 55% (the 
group of patients with adjuvant treatment of chemotherapy 
based on 5-fluorouracil) and, most importantly, the group of 
patients solely with the third pathological disease stage was 
not evaluated separately whist this is the group of patients 
who may benefit from such a course of treatment the most. 
Similarly, as in the previous metanalysis, the differences and 
doubts shown by the authors do not allow for any definite 
conclusions [9]. The summary of the discussed studies and 
metanalyses is presented in Table I.
In conclusion, as of the current moment, there is no 
definite scientific evidence providing grounds for the use 
of adjuvant chemotherapy in rectal cancer patients after 
preoperative chemoradiotherapy. It is necessary to carry out 
a randomised study, yet it should concern a homogenous 
and standardised group of patients with respect to their 
treatment in order to determine definite opinions concer-
ning the lack of benefits in adjuvant therapy. That is why 
currently, such therapy seems to be justified especially in 
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the group of patients with the N (+) stage (at least with the 
tumour location between 10 cm and 15 cm), similar to colon 
cancer; especially as there are no significant differences 
between colon cancer and rectal cancer as for their genetics 
and response to the palliative treatment [8].
Response
In the agreed recommendations concerning the con-
troversies in the primary treatment of rectal cancer, 77% 
of “panellists” opted for the use of adjuvant chemotherapy 
in the case of confirmed “positive” lymph nodes after neo-
adjuvant chemotherapy (ypN+). To sum up this subchapter 
of these recommendations concerning adjuvant treatment, 
the authors pointed to the use of adjuvant chemotherapy 
which should be considered the standard treatment in rectal 
cancer patients with the tumour location between 10 cm 
and 15 cm from the edge of the anus, with the presence 
of “involved” lymph nodes before neoadjuvant treatment 
(cN+) or after its completion (ypN+), and the chemotherapy 
regimen should contain oxaliplatin (47% votes for “yes”, 16% 
for “no”, 37% abstentions [1].
A similar sentiment was also seen in the most recent 
ESMO guidelines concerning the treatment of rectal cancer 
(Glynne-Jones et al. 2017), whose authors recommend con-
sidering the use of adjuvant treatment with chemotherapy 
in the third and second pathological disease stage (“yp”) 
with the presence of risk factors (“high-risk” group) after 
preoperative radiotherapy or chemoradiotherapy [10].
Also the NCCN recommendations (The National Com-
prehensive Cancer Network, version 4.2017) are definite 
with regards to the indications connected with the use of 
adjuvant chemotherapy after neoadjuvant chemotherapy. 
In patients with the T3N0 or (N+) or T4 stages and/or a non 
resectable tumour, after the neoadjuvant treatment with 
radiotherapy or chemoradiotherapy and surgical interven-
tion, it is recommended to use adjuvant chemotherapy 
based on oxaliplatin (regimens such as: FOLFOX or CAPOX, 
or 5-fluorouracil with folinic acid or capecitabine), and the 
entire perioperative systemic treatment should last 6 mon-
ths in total [11].
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Table I. The presentation of the studies and metanalyses
Author/year The number of 
subjects
Type of study DFS improvement OS improvement
Bosset et al. 2014
“EORTC 22921”
1011 The third-phase randomised clinical study NO NO
Aldo et al. 2014 655 The third-phase randomised clinical study NO NO
Breugom et al. 2015
“PROCTOR-SCRIPT”
437 The third-phase randomised clinical study NO NO
Hong et. al. 2014
“ADORE”
321 The second-phase randomised clinical study YES YES
Breugom et al. 2015 1198 The metanalysis of 4 studies: 
“I-CNR-RT”, “PROCTOR-SCRIPT”, “EORTC 2292”, 
CHRONICLE”
YES
With the primary 
tumour location 
between 10 and 15 cm
NO
Bujko et al. 2015 2398
2710
The metanalysis of 5 studies:
“EORTC 22921”, “Italian trial”, “PROCTOR/
SCRIPT”, “CHRONICLE”, “QUASAR”
 
The metanalysis of 4 studies:
“PETACC-6”, “CAO/ARO/AIO-04”, “ADORE”, 
“ECOG E3201”
NO
 NO
NO
 ----------
Zhao L et al. 2016 2973 The metanalysis of 4 studies:
“CAO/ARO/ AIO-04”, “PETACC-6”, “ADORE”, 
“CHRONICLE”
YES NO
DFS — disease-free survival, OS — overall survival
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